Radioisotopic detection of sentinel lymph nodes in clinically localized high-risk prostate cancer

被引:0
|
作者
Hinev, A. [1 ]
Klissarova, A. [2 ]
Ghenev, P. [3 ]
Kolev, N.
Chaushev, B. [2 ]
Chankov, P. [1 ]
Anakievski, D. [1 ]
Dyakov, S. [1 ]
Stratev, S.
Deliisky, T. [4 ]
机构
[1] St Marina Univ Hosp, Clin Surg 3, Div Urol, Varna, Bulgaria
[2] St Marina Univ Hosp, Dept Radiol, Varna, Bulgaria
[3] St Marina Univ Hosp, Dept Pathol, Varna, Bulgaria
[4] G Stranski Univ Hosp, Dept Surg Oncol, Pleven, Bulgaria
来源
JOURNAL OF BUON | 2009年 / 14卷 / 04期
关键词
gamma probe; lymph node dissection; lymphoscintigraphy; prostate cancer; sentinel lymph node; PELVIC LYMPHADENECTOMY; RADICAL PROSTATECTOMY;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To explore the efficacy of a radioisotopic (RI) method in detecting sentinel lymph nodes (SLNs), known as sites of harboring metastases, in localized high-risk prostate cancer (HRPC). Methods: The RI method was applied to 26 males with clinically localized HRPC, subjected to radical prostatectomy in 2006-2008. All had poor pathological characteristics: initial PSA > 15 ng/ml, Gleason score > 7, clinically suspected extracapsular extension, seminal vesicle invasion, and/or positive pelvic lymph nodes (LNs). The radiopharmaceutical (Tc-99m) was injected preoperatively at 4 zones of the periphery of the prostate. Tc-99m-nanocolloid particles were <= 80 nm in size, with total activity of 3 mCi (111 MBq), diluted in 2 mL. One hour after Tc-99m administration, a planar scintigraphy was performed on a gamma camera in anterior posterior and lateral projections. A high resolution collimator was used, gathering impulses up to 300 000 per frame. The precise location of the SLNs was determined intraoperatively by a gamma probe. The LNs removed by extended pelvic lymphadenectomy were arranged on an anatomical template, examined ex vivo by the gamma probe and scanned again. The LNs were cleaned from the adjacent fatty tissue, fixed in neutral formalin, and then processed separately for histological and immunohistochemical examination. Results: The number of surgically removed LNs ranged from 9 to 38 (mean 13), and the SLAs from 1 to 7 (mean 3). The SLNs were visualized on lymphoscintigraphy as strictly defined, round zones of high activity and were easily recognized intraoperatively by the gamma probe. The scintigraphic images of the scanned anatomical templates correlated well with those prior to surgery. Histology confirmed LN metastases in 11 cases. 94% of the metastatic LNs were SLNs, accurately detected by the RI method. Only 2 metastatic LNs showed no activity prior to, and during the operation. Most of the metastatic LNs (62%) were SLNs, located out of the obturator fossa. Conclusion: The radioisotopic detection of the SLNs in HRPC is an objective and sensitive method that aids the surgeon to take a proper decision regarding the scope of the pelvic LN dissection in each particular case.
引用
收藏
页码:661 / 667
页数:7
相关论文
共 50 条
  • [31] Contemporary management of high-risk localized prostate cancer
    Garzotto M.
    Hung A.Y.
    Current Urology Reports, 2010, 11 (3) : 159 - 164
  • [32] Surgical management of high-risk, localized prostate cancer
    Wilkins, Lamont J.
    Tosoian, Jeffrey J.
    Sundi, Debasish
    Ross, Ashley E.
    Grimberg, Dominic
    Klein, Eric A.
    Chapin, Brian F.
    Nyame, Yaw A.
    NATURE REVIEWS UROLOGY, 2020, 17 (12) : 679 - 690
  • [33] Optimizing the Management of High-Risk, Localized Prostate Cancer
    Sundi, Debasish
    Jeong, Byong Chang
    Lee, Seung Bae
    Han, Misop
    KOREAN JOURNAL OF UROLOGY, 2012, 53 (12) : 815 - 820
  • [34] Systemic treatments for high-risk localized prostate cancer
    Pignot, Geraldine
    Maillet, Denis
    Gross, Emmanuel
    Barthelemy, Philippe
    Beauval, Jean-Baptiste
    Constans-Schlurmann, Friederike
    Loriot, Yohann
    Ploussard, Guillaume
    Sargos, Paul
    Timsit, Marc-Olivier
    Vincendeau, Sebastien
    Pasticier, Gilles
    Borchiellini, Delphine
    NATURE REVIEWS UROLOGY, 2018, 15 (08) : 498 - 510
  • [35] Lymph node staging in clinically localized prostate cancer
    CC Parker
    J Husband
    DP Dearnaley
    Prostate Cancer and Prostatic Diseases, 1999, 2 : 191 - 199
  • [36] Lymph node staging in clinically localized prostate cancer
    Parker, CC
    Husband, J
    Dearnaley, DP
    PROSTATE CANCER AND PROSTATIC DISEASES, 1999, 2 (04) : 191 - 199
  • [37] Neoadjuvant therapy for high-risk localized prostate cancer
    Evan Y. Yu
    William K. Oh
    Current Oncology Reports, 2003, 5 (3) : 250 - 257
  • [38] High-risk localized prostate cancer: Integrating chemotherapy
    Oh, WK
    ONCOLOGIST, 2005, 10 : 18 - 22
  • [39] Surgical management of high-risk, localized prostate cancer
    Lamont J. Wilkins
    Jeffrey J. Tosoian
    Debasish Sundi
    Ashley E. Ross
    Dominic Grimberg
    Eric A. Klein
    Brian F. Chapin
    Yaw A. Nyame
    Nature Reviews Urology, 2020, 17 : 679 - 690
  • [40] Systemic treatments for high-risk localized prostate cancer
    Géraldine Pignot
    Denis Maillet
    Emmanuel Gross
    Philippe Barthelemy
    Jean-Baptiste Beauval
    Friederike Constans-Schlurmann
    Yohann Loriot
    Guillaume Ploussard
    Paul Sargos
    Marc-Olivier Timsit
    Sébastien Vincendeau
    Gilles Pasticier
    Delphine Borchiellini
    Nature Reviews Urology, 2018, 15 : 498 - 510